| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 9.40▲ | 9.42▼ | 9.45▼ | 10.24▼ | 11.17▼ |
| MA10 | 9.40▲ | 9.44▼ | 9.27▲ | 10.95▼ | 10.53▼ |
| MA20 | 9.41▲ | 9.22▲ | 9.17▲ | 11.12▼ | 9.23▲ |
| MA50 | 9.43▼ | 9.74▼ | 10.71▼ | 10.54▼ | 8.60▲ |
| MA100 | 9.30▲ | 10.76▼ | 10.91▼ | 9.14▲ | 7.00▲ |
| MA200 | 9.17▲ | 10.92▼ | 11.45▼ | 8.73▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | 0.066▲ | 0.135▲ | -0.330▼ | 0.133▲ |
| RSI | 50.526▲ | 50.332▲ | 42.822▼ | 36.277▼ | 50.242▲ |
| STOCH | 67.407 | 44.581 | 77.909 | 43.417 | 64.646 |
| WILL %R | -22.222▲ | -31.098 | -24.402▲ | -77.624▼ | -67.511 |
| CCI | 64.368 | 15.361 | 64.959 | -149.822▼ | 5.436 |
|
Wednesday, August 13, 2025 12:36 AM
Zevra Therapeutics Inc (ZVRA) reports robust Q2 performance with significant revenue growth and strategic advancements, despite facing market adoption challenges for new treatments.
|
|
Tuesday, August 12, 2025 05:45 PM
Zevra Therapeutics reports strong Q2 2025 results with $25.9M in revenue, MIPLYFFA growth, and a $150M asset sale.
|
|
Tuesday, August 12, 2025 05:43 PM
Zevra Therapeutics, Inc. ( NASDAQ: ZVRA) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 8.88 | 9.68 | 8.82 | 9.43 | 2,647,577 |
| 14/08/25 | 9.40 | 9.445 | 8.62 | 8.90 | 3,389,988 |
| 13/08/25 | 10.34 | 10.41 | 8.84 | 9.43 | 6,995,500 |
| 12/08/25 | 11.80 | 11.907 | 11.51 | 11.76 | 1,714,365 |
| 11/08/25 | 12.22 | 12.22 | 11.30 | 11.70 | 1,249,952 |
| 08/08/25 | 12.104 | 12.22 | 11.575 | 12.02 | 985,818 |
| 07/08/25 | 11.73 | 12.24 | 11.594 | 12.13 | 1,456,300 |
| 06/08/25 | 11.43 | 11.49 | 11.01 | 11.48 | 680,543 |
| 05/08/25 | 11.255 | 11.44 | 11.16 | 11.44 | 624,757 |
| 04/08/25 | 11.06 | 11.34 | 10.90 | 11.25 | 572,527 |
|
|
||||
|
|
||||
|
|